Retracted: MicroRNA‐590‐5p functions as a tumor suppressor in breast cancer conferring inhibitory effects on cell migration, invasion, and epithelial–mesenchymal transition by downregulating the Wnt–β‐catenin signaling pathway

Abstract

Breast cancer remains one of the foremost primary causes of female morbidity and mortality worldwide. During the current study, the effect of miR-590-5p and paired-like homeodomain transcription factor 2 (PITX2) on proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) of human breast cancer via the Wnt-β-catenin signaling pathway was investigated. Breast cancer-related genes and related signaling pathways were obtained from KEGG database. The PITX2 regulatory microRNA was predicted. To define the contributory role by which miR-590-5p influences the progression of breast cancer, the interaction between miR-590-5p and PITX2 was explored; the proliferation, invasion, and migration abilities as well as the tumor growth and metastasis in nude mice were detected following the overexpression or silencing of miR-590-5p. PITX2 was determined to share a correlation with breast cancer and miR-590-5p was selected for further analysis. PITX2, Wnt-1, β-catenin, N-cadherin, and vimentin all displayed higher levels, while miR-590-5p and E-cadherin expression were lower among breast cancer tissues than in the adjacent normal tissue. After overexpression of miR-590-5p or si-PITX2, the expression of E-cadherin was markedly increased, decreases in the expression of Wnt-1, β-catenin, N-cadherin, and vimentin, as well as inhibited cell proliferation, invasion, migration, metastasis, and EMT were observed. This study provides evidence suggesting that the transfection of overexpressed miR-590-5p can act to alleviate the effects of breast cancer demonstrating an ability to inhibit the processes of cell proliferation, migration, and invasion as well as EMT by suppressing the expression of PITX2 and activation of the Wnt-β-catenin pathway.

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

“…Previous studies have found dysregulation of miR‐590‐5p in a number of different types of cancer cells . Thus, we examined the correlation of miRNA with disease progression of NSCLC.…”

“…Scale bar, 100 μm and n = 3 NSCLC tissues 2), TGF-βRII (transforming growth factor beta receptor 2), 23 NF90/ VEGFA (nuclear factor 90/vascular endothelial growth factor A) 20,21 and GAB1 (GRB2 associated binding protein A) 39 which promote cancer growth and progression. 22,26,27,40,41 Likewise, miR-590-5p oncogenic properties were reported in gastric, cervical, vulvar, and clear cell renal cancer, where it targets RECK (reversion inducing cysteine rich protein with kazal motifs), 32 CHL1 (close homolog of L1), 28 TGF-βRII, 29 and PBRM1 (Polybromo 1), 30 respectively, and regulates cell proliferation, migration and invasion of cancer cells. However, the role of circulating miR-590-5p in blood plasma has not been reported.…”

“…Recently, cellular miR‐590‐5p has been shown to play important roles in tumorigenesis and metastasis of various cancers where it was shown to function as either a tumor suppressor or an oncomiR based on its target(s) in the respective cancers. Its expression was found to be downregulated in breast, hepatocellular, colorectal, and lung cancer tissues, and targeted the Wnt/β‐catenin pathway, SOX2 (SRY‐box 2), TGF‐βRII (transforming growth factor beta receptor 2), NF90/VEGFA (nuclear factor 90/vascular endothelial growth factor A) and GAB1 (GRB2 associated binding protein A) which promote cancer growth and progression . Likewise, miR‐590‐5p oncogenic properties were reported in gastric, cervical, vulvar, and clear cell renal cancer, where it targets RECK (reversion inducing cysteine rich protein with kazal motifs), CHL1 (close homolog of L1), TGF‐βRII, and PBRM1 (Polybromo 1), respectively, and regulates cell proliferation, migration and invasion of cancer cells.…”

“…2 With this goal in mind, the present study investigated circulating miR-590-5p dysregulation in blood plasma samples of NSCLC patients compared to non-cancerous healthy control plasma samples. miR-590-5p has been found to be dysregulated in various other cancers, such as colorectal, [20][21][22] hepatocellular, [23][24][25] breast, 26,27 cervix, 28 vulvar, 29 renal, 30,31 and gastric, 32,33 among others, and has been reported as both oncogenic and/or tumor suppressive.…”

“…NSCLC cohort (n = 80) consisted of individuals with a median age of 55 ± 14.95 years in the range 40-70 years, and an age-matched healthy control cohort (n = 80) with a median age of 50.50 ± 15.50 years in the range 34-66 years. Within the NSCLC cohort, study subjects were segregated on the basis of their staging; for example, stage II (n = 19) 23.75% with a median age of 56 ± 13.10 years, stage III (n = 54) 67.5% with a median age of 52 ± 12.90 years, and stage IV (n = 7) 8.75% with a median age of 64 ± 5.70 years.Previous studies have found dysregulation of miR-590-5p in a number of different types of cancer cells [20][21][22]24,[26][27][28][29]31,33. Thus, we examined the correlation of miRNA with disease progression of NSCLC.…”